V ery late stent thrombosis (VLST; ie, beyond 1 year after stent implantation) is a potential complication of percutaneous coronary intervention with bare-metal stents (BMS) and drug-eluting stents (DES). Although VLST is rare, it may lead to catastrophic complications, such as myocardial infarction (MI) and death. 1,2 Histopathology showed that delayed arterial healing with uncovered and malapposed stent struts may contribute to VLST. 3, 4 Guagliumi et al 5 showed in vivo that the presence of uncovered stent struts as assessed by optical coherence tomography (OCT) and positive vessel remodeling by intravascular ultrasound were associated with LST or VLST after DES. The presence of neoatherosclerosis was as well revealed as one of the potential triggers of VLST in both BMS and DES. 6-8 However, a comprehensive assessment of the characteristics, potential mechanisms, and differences between BMS and DES' VLST is lacking. Moreover, the characteristics of neoatherosclerosis in VLST with either DES or BMS remain largely unclear. Therefore, we systematically analyzed OCT in patients with VLST and compared the findings between BMS and DES.
OCT in Very Late Stent Thrombosis
we included only patients presenting with acute MI or unstable angina. Study exclusion criteria were hemodynamic instability, age <18 years, and life expectancy <6 months because of noncardiac condition. We included all consecutive patients with VLST who had diagnostic OCT imaging performed during the acute presentation between October 10, 2010, and April 7, 2015. Written informed consent was obtained from all participating patients, and the protocol was approved by the local ethics committees. In-hospital outcomes including cardiac death, repeated revascularization, and repeated MI were assessed.
OCT Image Acquisition and Analysis
A conventional angioplasty guidewire (0.014″) was advanced distal to the region of interest and then the 2.7F FD-OCT catheter (Dragonfly, St. Jude Medical, St. Paul, MN) was advanced over the guidewire beyond the region of interest. In general, in patients presenting with TIMI (Thrombolysis in Myocardial Infarction) flow grades 2 and 3, OCT was performed before any intervention, whereas for the case with TIMI 0 or 1 OCT was performed after manual thrombectomy or predilatation using small-sized balloons. The images were calibrated by automated adjustment of the Z-offset and automated pullback was set at 20 mm/s. Data were acquired using a commercially available OCT system (C7-XR; OCT Imaging System, St. Jude Medical, St. Paul, MN) and were digitally stored. During imaging acquisition, blood was displaced by injection of iso-osmolar contrast dye.
An independent core laboratory (Cardiovascular Imaging Core Laboratory, Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, OH) analyzed all OCT images. The images were analyzed by 2 independent investigators blinded to the angiographic and clinical data. OCT analysis were performed using dedicated software with an automated contour-detection algorithm (Off-line Review Software, version E.0.2; St. Jude Medical). All cross-sectional images were initially screened for quality assessment and excluded from analysis if any portion of the stent was out of the screen if a side branch occupied >45 of the cross section or if the image had poor quality caused by residual blood, artifact, or reverberation. 10 Qualitative image assessment was performed in every frame, whereas quantitative measurements were performed every 0.6 mm along the entire stented segment. 10 For the morphometric analysis, standard definitions of cross-sectional area and volume measurements were applied as previously reported. 10 Stent, lumen, and neointimal hyperplasia cross-sectional areas were measured at 0.6-mm axial increments throughout the entire length of the stent, and respective volumes were calculated according to the Simpson rule. When the thrombus with high attenuation was observed in the stent, the lumen contour was allowed to be extrapolated behind the thrombus when the lumen contour was visible in 3 quadrants. When the stent was covered by thrombus with high signal attenuation, stent area was traced only if at least 1 strut was clearly visible in every quadrant. 11 Proximal and distal references were measured at the site with the largest lumen within 5 mm proximal and distal to the stented segment. Strut-lumen distance was determined based on automated measurements performed from the center of the strut blooming to the luminal contour of the artery wall. Malapposition was defined when this distance was higher than the sum of strut thickness plus abluminal polymer thickness according to stent manufacturer's specifications plus a compensation factor of 18 μm to correct for strut blooming. 10 Struts were covered if tissue could be identified above the stent struts or uncovered if no evidence of tissue could be imaged above the struts. Percentage of covered and uncovered struts was calculated as the number of struts with/without distinct overlying tissue, in which the luminal reflection of the strut surface was directly interfacing with the lumen, divided by the total number of analyzable struts. Evagination was defined as outward bulging of the vessel wall between apposed stent struts more than the actual strut thickness. 11 Stent underexpansion was defined when the minimum stent area/mean (proximal and distal) reference area was <80% if both references were available, <90% if only the distal reference was available, or <70% if only the proximal reference was available. Neointima was defined as the tissue between the luminal contour and stent contour. In-stent restenosis was defined as maximum percent neointima area obstruction >70%. 11 Homogenous neointima was identified as signal-rich regions with low attenuation. Calcified neointima had a well-delineated, signal-poor region with sharp borders. Lipid neointima was defined as signal-poor regions with diffuse borders and high attenuation. 12 Neoatherosclerosis was defined as the lipid or calcified neointima. 13 In lipid neointima, fibrous cap thickness was computed as the mean of 3 evenly distributed measurements along the fibrous cap. 14 Thin-cap fibroatheroma (TCFA) neointima was defined as lipid neointima with a fibrous cap thickness ≤65 μm at the thinnest part.
Intraluminal thrombus was identified as intraluminal masses with irregular contour floating within the lumen or attached to the intimal surface. Red thrombus had high backscattering with signal-free shadowing, and white thrombus was signal rich and had low backscattering. 15, 16 Microvessel was defined as small vesicular or tubular structures with diameters of ≤200 μm. 17 Bifurcation stenting was defined as when thrombus at the bifurcation site in case of stent in main and side branch was observed. 11
Statistical Analysis
All statistical analyses were performed using SAS (version 9.4) software (SAS Institute, Cary, NC). Continuous variables are expressed as mean±SD or median (interquartile range), and categorical variables are
WHAT IS KNOWN
• Very late stent thrombosis is a catastrophic event that may occur beyond 1 year after stent implantation with either bare-metal stents and drug-eluting stents.
• There are various mechanisms that have been associated with very late stent thrombosis, such as malapposed struts, uncovered struts, neoatherosclerosis, and stent underexpansion.
WHAT THE STUDY ADDS
• Malapposed struts and stent underexpansion were found more frequently in drug-eluting stents than in bare-metal stents patients, whereas neoatherosclerosis was frequently observed in bare-metal stents.
• Neoatherosclerosis and lipid-containing neointima had more longitudinal extension in bare-metal stents than in drug-eluting stents.
• Optical coherence tomography is an important tool to identify the mechanism of very late stent thrombosis and could be used to guide revascularization procedures. expressed as count (percentage). For continuous variables, the difference between DES and BMS for all patients or patients with neoatherosclerosis was analyzed by Mann-Whitney U tests, and categorical variables were compared using Fisher exact test. The difference between regions with and without thrombus was compared using generalized estimating equations with exchangeable correlation to account for the clustering of values within each OCT pullback. The association between follow-up days and different lipid plaque measurements by OCT was assessed using Pearson correlation coefficient, and Pearson correlation coefficients of BMS group and DES group were compared using Fisher z transformation. Values are median (interquartile range) or n (%). BMS indicates bare-metal stent; CAD, coronary artery disease; DES, drug-eluting stent; NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
Results

Clinical Characteristics and In-Hospital Outcomes
A total of 61 patients with VLST (42 DES and 19 BMS) were included (Figure 1 ). Clinical and angiographic characteristics are shown in Table 1 . Forty-eight patients (78.7%) presented with ST-segment-elevation MI. The median duration from implantation to VLST presentation was 51.4 (IQR, 23.1-69.3) months in the DES and 69.9 (IQR, 41.5-134.0) months in the BMS group (P=0.011). There were no significant differences for in-hospital outcomes such as death (2. 
Mechanisms of VLST
Overall, 60 (98.3%) lesions showed intraluminal thrombus (100% in DES lesions versus 94.7% in BMS lesions; P=0.31). Red thrombus was predominant in 40 (65.6%), and white thrombus was predominant in 20 cases (32.8%).
Uncovered and malapposed stent struts were observed in 70.5% (43/61) and 62.3% (38/61) of patients, respectively, whereas neoatherosclerosis was revealed in 49.2% (30/61; Table 2 ). Stent fracture was observed in only 1 patient with DES. Evagination was observed in only 5 DES. In only 4.9% of cases with VLST, intrastent restenosis without neoatherosclerosis was observed. Stent underexpansion was observed in 42.4% of patients. Malapposed struts and neoatherosclerosis in the same stent were seen in 10 patients (16.4%; Figure 2 ).
Uncovered and malapposed struts and stent underexpansion were more frequently demonstrated in DES than in BMS patients, whereas neoatherosclerosis was more commonly observed in the latter ( Table 2 ).
Strut Level Analysis of Uncovered and Malapposed Struts
The percentage of uncovered (11.45% [2.36-23.86] and 0.00% [0.00-3.77]; P<0.001) and malapposed struts (2.91% [0.39-7.76] and 0.00% [0.00-1.61]; P<0.001) were significantly higher in DES than in BMS patients (Table 3) . The frequency of patients with malapposed struts were significantly greater in drug-eluting stent (DES) than in baremetal stent (BMS). Neoatherosclerosis was more frequently observed in BMS than in DES patients. OCT in Very Late Stent Thrombosis Volumetric assessment of malapposition, as well as the distribution of uncovered and malapposed struts along the stented segment, consistently confirmed these differences (Table 3 ).
OCT Findings of Thrombus Region Versus Nonthrombus Region
We analyzed the OCT finding between regions with and without thrombus. The percentage of uncovered struts was significantly greater in the thrombus than in nonthrombus region (14.56±21.55% and 8.70±11.67%; P=0.043); likewise, the percentage of malapposed struts while not statistically significant was also higher in the former (7.22±17.42% and 2.89±5.16%, respectively; P=0.08; Table I in the Data  Supplement) . (Figure 4 ). Among patients with neoatherosclerosis, malapposed strut were frequently seen in DES (47.1%) compared with BMS (15.4%; Table 4 ). In BMS, the longitudinal extension of the lipid neointima was positively correlated with the duration after stent implantation (r=0.581; P=0.036), whereas in DES there was no statistically significant correlation (r=0.080; P=0.774; Figure 5 ). 
Neoatherosclerosis
Discussion
The present study has the large population of VLST analyzed by OCT. Its major findings were (1) patients with VLST post DES or BMS implantation had a wide variety of abnormal findings, such as neoatherosclerosis, uncovered strut, malapposed strut, and stent underexpansion; (2) uncovered strut, malapposed strut, and stent underexpansion were more frequently observed in DES; (3) neoatherosclerosis, lipid neointima, and TCFA neointima were more frequently observed and had more diffuse pattern of distribution in BMS than in DES.
The present study demonstrated that VLST in both DES and BMS was multifactorial. The association of malapposition with VLST has previously been highlighted in pathology. 4 Cook et al 18 reported higher incidence of strut malapposition and positive vessel remodeling in cases with VLST compared with those without VLST. One recent study demonstrated that malapposition was strongly correlated with VLST. 11, 19 OCT studies demonstrated that 18 patients with LST or VLST after DES implantation had high percentage of uncovered and malapposed struts (12.27% and 4.60%). 5 The present study demonstrated that uncovered strut and malapposition strut Comparison of lipid neointima between drug-eluting stents (DES) and bare-metal stents (BMS). The percentage of frames (longitudinal extension) with lipid neointima, maximum consecutive lipid and thin-cap fibroatheroma (TCFA) neointima length were significantly lower in DES than in BMS. Nonetheless, no significant differences in the minimum fibrous cap (FC) thickness were revealed. Data are represented as boxplot with medians and 25th to 75th percentiles (boxes) and minimum to maximum (whiskers). OCT in Very Late Stent Thrombosis rates were higher in DES than in BMS with VLST (11.45% and 2.91% in DES and 0.00% and 0.00% in BMS, respectively; P=0.001). Because intravascular imaging was not performed in the index procedure, the present study was unable to distinguish between persistent malapposition related to suboptimal sizing or from late acquired malapposition caused by positive vessel remodeling due, for example, to hypersensitivity reactions. 20 Although underexpansion was frequent in cases with malapposition, especially for DES, it is difficult to determine whether it was present in the index procedure because the diagnosis of underexpansion was delivered by the reference area at the onset of stent thrombosis. Although our findings are insightful and provide comprehensive assessment of VLST mechanisms, it is important to emphasize that the lack of baseline OCT remains as a limitation; nonetheless, it is remarkably important that clinicians are cognizant of variables that can potentially play a role in VLST and can be modified and optimized in the index procedure (ie, sizing, expansion, and apposition).
Neoatherosclerosis has been consistently correlated with late thrombotic events post stent implantation. 7,16,21-23 One pathological study demonstrated that in-stent neoatherosclerosis accounts for 15% of VLST in DES and 83% of VLST in BMS. 11 We observed a trend toward more neoatherosclerosis in BMS than in DES (40.5% in DES and 68.4% in BMS; P=0.056). However, this is inconsistent with previous OCT studies showing that around 20% of DES with VLST had the lipid neointima 5, 24 and all BMS had TCFA neointima. 25 Possible explanation for the discrepancy might be the duration between stent implantation and VLST episode (ie, longer in our analysis) 26 and the larger population of the present study.
The present study showed that neoatherosclerosis showed more diffuse pattern in BMS than in DES. On the contrary, DES with neoatherosclerosis has more malapposed strut simultaneously. This difference might be because of the difference of the mechanism of neoatherosclerosis between DES and BMS. In-stent neoatherosclerosis occur in years after stent implantation and rapidly in DES when compared with BMS. 7 One histological paper demonstrated that accelerated neoatherosclerosis after DES is likely a direct consequence of delayed vascular healing and inflammation caused by the antiproliferative drug and polymer although a continuous correlation of its magnitude with the degree of delayed vascular healing cannot be concluded to date. 5 On the contrary, the longitudinal extension of neoatherosclerosis in BMS was correlated with the time after implantation. Our data support the concept that the neoatherosclerosis observed with DES is more aggressive and progresses to acute coronary syndrome earlier than with BMS. 7 The amount of neointimal hyperplasia was greater and the frequency of restenosis (11.9% in DES and 42.1% in BMS; P=0.015) was higher in BMS than in DES. However, the restenosis without neoatherosclerosis was rarely observed in both DES and BMS, whereas more than half of cases with neoatherosclerosis did not show in-stent restenosis. These present findings indicate that restenosis and excessive neointimal hyperplasia itself did not directly relate to VLST, which is similar to the acute coronary syndrome of native vessel (ie, plaque rupture). 27, 28 For interventional cardiologists, the therapeutic strategy for stent thrombosis still remains to be challenge and there are no current consensus to treat stent thrombosis. 29 However, finding an accurate diagnosis for the causes of stent thrombosis is necessary for appropriate therapy. The present findings might be helpful for deciding the strategy of VLST. The differences in the frequency and longitudinal extension of neoatherosclerosis were clinically important to potentially help customize the interventional strategy in this setting. For example, the required extension (diffuse versus focal) and type of intervention (ie, plain-balloon, drug-eluting balloon, and stent implantation) may be different between BMS and DES. Moreover, repeat MI was occurred only in 4 patients with neoatherosclerosis, no patients with other abnormal OCT findings such as malapposed and uncovered struts, and in all these patients only plain old balloon angioplasty was performed. Nonetheless, there are small population with VLST in the current study, these findings indicated that we might need to implant the stent for the patients in VLST with neoatherosclerosis. In either way, the intravascular imaging such as OCT is important to find the mechanism and decide the strategy for patients with VLST.
Limitations
First, this is observational study and population size is still underpowered even though this is the large population report of VLST with OCT imaging. Second, there is no serial OCT data at the time of stent implantation. Third, there is no control group and no long clinical outcome data. Fourth, the frequency of new-generation DES was very low in the present study (13.1%); therefore, differences between early generation and late-generation DES were not investigated. Fifth, it is difficult to detect any findings behind the red thrombus in the stented segment because of the high attenuation Finally, the time difference post stent implantation for VLST in BMS and DES may have impacted our results; nonetheless, this is a limitation that cannot be controlled as patients were included when they presented VLST. Importantly, however, the longitudinal extension of the lipid neointima (ie, neoatherosclerosis) was positively correlated with the duration after stent implantation (r=0.581; P=0.036) in BMS, whereas in DES there was no statistically significant correlation (r=0.080; P=0.774), which indicates that neoatherosclerosis in DES more rapidly and aggressively progressed compared with BMS and therefore was less impacted by the duration of stent implantation. Actually in the present study, there are no significant differences of the frequency of malapposed strut (73.7% and 57.1%; P=0.264) and neoatherosclerosis (36.8% and 54.8%; P=0.270) between cases with stent duration <3 years and ≥3 years after implantation. Besides, we performed multivariate data analysis for continuous and binary outcomes in Tables 2 through 4 adjusting for the time difference after stent implantation. For binary outcome, the results were presented as odds ratio (multivariate logistics regression models were used), and for continuous outcomes the results were presented as linear coefficients β (multivariate linear regression models were used; Tables III and IV in the Data Supplement). The uncovered struts, malapposed struts, and stent underexpansion were still more frequent in DES than in BMS even after adjusting the time difference (Table III in the Data Supplement) . Likewise, for the strut level analysis, the percentage of uncovered and malapposed struts were significantly higher in DES than in BMS (Table III in  the Data Supplement ) . Moreover, the percentage of frames (longitudinal extension) with neoatherosclerosis and lipid neointima were lower in DES and maximum consecutive lipid and TCFA neointima length were significantly shorter in DES than in BMS after adjusting (Table IV in 
Conclusions
OCT imaging demonstrated that VLST in DES and BMS had a wide variety of abnormal findings, such as neoatherosclerosis, uncovered strut, malapposed strut, and stent underexpansion. Uncovered strut, malapposed strut, and stent underexpansion were more frequently observed in DES than in BMS. Neoatherosclerosis, lipid neointima, and TCFA neointima were more Figure 5 . Correlation of the percentage of frames with lipid neointima with the stent duration. In drug-eluting stents (DES), there was no significant correlation between percentage of frames with lipid neointima and stent duration, whereas the longitudinal distribution of the lipid neointima was positively correlated with the duration after stent implantation in bare-metal stents (BMS). OCT in Very Late Stent Thrombosis frequently observed and had more diffuse pattern of distribution in BMS.
